591 related articles for article (PubMed ID: 15790985)
1. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
2. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
3. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
4. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
5. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
[TBL] [Abstract][Full Text] [Related]
6. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
[TBL] [Abstract][Full Text] [Related]
7. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
8. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
9. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
[TBL] [Abstract][Full Text] [Related]
11. Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients.
Adachi M; Aizawa H; Ishihara K; Ohta K; Sano Y; Taniguchi H; Nakashima M
Respir Med; 2008 Jul; 102(7):1055-64. PubMed ID: 18394875
[TBL] [Abstract][Full Text] [Related]
12. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate.
Lundbäck B; Rönmark E; Lindberg A; Jonsson AC; Larsson LG; Pétavy F; James M
Respir Med; 2006 Jan; 100(1):2-10. PubMed ID: 16243498
[TBL] [Abstract][Full Text] [Related]
13. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma.
Fardon T; Haggart K; Lee DK; Lipworth BJ
Respir Med; 2007 Jun; 101(6):1218-28. PubMed ID: 17178217
[TBL] [Abstract][Full Text] [Related]
14. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
[TBL] [Abstract][Full Text] [Related]
15. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
Bourbeau J; Christodoulopoulos P; Maltais F; Yamauchi Y; Olivenstein R; Hamid Q
Thorax; 2007 Nov; 62(11):938-43. PubMed ID: 17557771
[TBL] [Abstract][Full Text] [Related]
16. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
17. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
18. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma.
Weiler JM; Nathan RA; Rupp NT; Kalberg CJ; Emmett A; Dorinsky PM
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):65-72. PubMed ID: 15702819
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids.
You-Ning L; Humphries M; Du X; Wang L; Jiang J
Int J Clin Pract; 2005 Jul; 59(7):754-9. PubMed ID: 15963199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
